

GLAXOSMITHKLINE PLC  
Form 6-K  
May 09, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an  
ris

Date:  
9 May 2012

Name of applicant: GlaxoSmithKline plc  
Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 4,444,541  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 15,000,000  
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 5,353,854  
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 14,090,687

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc  
Name of scheme: GlaxoSmithKline Share Option Plan - ADS  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 3,247,706  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 15,000,000  
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 12,710,138  
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 5,537,568

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc  
Name of scheme: Glaxo Wellcome UK Share Option Scheme  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 5,119,750  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has

been applied for):

Less: Number of securities issued/allotted under scheme(s) 0  
during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted at 5,119,750  
end of period:

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant GlaxoSmithKline plc  
:  
Name of scheme: Glaxo Wellcome International Share Option Scheme  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from 13,267,156  
previous return:  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0  
Less: Number of securities issued/allotted under scheme(s) 0  
during period (see LR3.5.7G):  
Equals: Balance under scheme(s) not yet issued/allotted at 13,267,156  
end of period:

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an  
ris

Date:  
9 May 2012

Name of applicant : GlaxoSmithKline plc  
Name of scheme: Glaxo Wellcome 1999 Share Option Plan  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 1,040,000  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has 0 been applied for):  
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0  
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period: 1,040,000

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Name of applicant : GlaxoSmithKline plc  
Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 163,606  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0  
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0  
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 163,606

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc  
Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 275,420  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0  
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0  
275,420

Equals: Balance under scheme(s) not yet issued/allotted at  
end of period:

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc  
Name of scheme: SmithKline Beecham 1989 Executive Share Option  
Plan - Unapproved - Ordinary  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from  
previous return: 100,000  
Plus: The amount by which the block scheme(s) has been  
increased since the date of the last return (if any increase 0  
has been applied for):  
Less: Number of securities issued/allotted under scheme(s) 0  
during period (see LR3.5.7G):  
Equals: Balance under scheme(s) not yet issued/allotted at 100,000  
end of period:

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc  
Name of scheme: GlaxoSmithKline Savings Related Share Option Scheme  
Period of return: From: 1 November 2011 To: 30 April 2012  
Balance of unallotted securities under scheme(s) from previous return: 7,793,416  
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0  
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 3,787,708  
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 4,005,708

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 09, 2012

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc